1353623-41-2

Upstream product

• 1353628-68-8 tert-butyl (2S)-2-(7-hydroxy-5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidin-2-yl)piperidine-1-carboxylate 
• 1353628-07-5 tert-butyl (2S)-2-(5-amino-1H-pyrazol-3-yl)piperidine-1-carboxylate 
• 1353628-69-9 (S)-5,7-dichloro-2-(piperidin-2-yl)pyrazolo[1,5-a]pyrimidine hydrochloride 
• 1260587-50-5 (S)-tert-butyl 2-(2-cyanoacetyl)piperidine-1-carboxylate 
• 200184-53-8 (S)-1-tert-butyl 2-methyl piperidine-1,2-dicarboxylate 
• 203056-27-3 tert-butyl (2S)-2-{[methoxy(methyl)amino]-carbonyl}piperidine-1-carboxylate 
• 503-29-7 azetidine 
• 40499-83-0 pyrrolidin-3-ol 
• 1353628-61-1 (S)-N-(4-chloro-2-(2-(5,7-dichloropyrazolo[1,5-a]pyrimidin-2-yl)piperidine-1-carbonyl)phenyl)methanesulfonamide 
• 26250-84-0 (S)-(-)-1-(tert-butoxycarbonyl)-2-piperidinecarboxylic acid 

Relevant academic research and scientific papers

PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS

The invention provides compounds of Formula I or Formula II: (I), (II) or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.